Drug intelligence / Profile preview

V950

Development stage: Phase 1
Lead developer: Merck
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

V950 is a therapeutic vaccine developed by Merck & Co. for the treatment of Alzheimer's disease. It targets beta amyloid A4 protein (APP), acting as an APP inhibitor to reduce or prevent the accumulation of beta-amyloid plaques in the brain—a hallmark of Alzheimer's pathology. The drug was evaluated in clinical trials for its safety, tolerability, and immunogenicity in patients with Alzheimer's disease but development has been discontinued[1][2].

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on V950.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V950.

Explore the full profile